Published in Folia Neuropathol on January 01, 2014
A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med (2006) 8.12
Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke (2009) 5.28
Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology (2013) 2.99
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol (2003) 2.14
Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12
Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol (2008) 1.62
Reliability of brain CT evaluation by stroke neurologists in telemedicine. Neurology (2012) 1.54
Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. Circ J (2010) 1.45
Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord (2007) 1.41
Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci (2006) 1.40
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep (2012) 1.36
Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord (2007) 1.35
Adherence to antiparkinson medication in a multicenter European study. Mov Disord (2009) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Mitochondrial cytopathies. J Neurol (2003) 1.28
Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol (2010) 1.24
Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate. Brain Res (2004) 1.23
EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord (2014) 1.23
Genes associated with Parkinson syndrome. J Neurol (2008) 1.21
The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells (2007) 1.21
Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem Int (2006) 1.17
Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord (2004) 1.09
Transdermal rotigotine for the perioperative management of Parkinson's disease. J Neural Transm (Vienna) (2010) 1.08
The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. Br J Pharmacol (2004) 1.07
Different odor tests contribute differently to the evaluation of olfactory loss. Chem Senses (2007) 1.05
Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord (2009) 1.02
Depression and Parkinson's disease. J Neurol (2004) 1.02
Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci (2006) 1.02
Primary skin fibroblasts as a model of Parkinson's disease. Mol Neurobiol (2012) 1.01
Utility of the WHO-Five Well-being Index as a screening tool for depression in Parkinson's disease. Mov Disord (2010) 1.00
A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease. J Neurol (2008) 1.00
Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci (2009) 1.00
Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci (2009) 0.99
Biopsies of olfactory epithelium in patients with Parkinson's disease. Mov Disord (2009) 0.99
Early relapses in primary CNS lymphoma after response to polychemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol (2008) 0.97
Olfactory dysfunction as a diagnostic marker for Parkinson's disease. Expert Rev Neurother (2009) 0.95
Early complete response during chemotherapy predicts favorable outcome in patients with primary CNS lymphoma. Neuro Oncol (2010) 0.95
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol (2010) 0.93
Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol (2015) 0.93
Thymoquinone protects dopaminergic neurons against MPP+ and rotenone. Phytother Res (2009) 0.92
Selectivity in the photodimerization of 6-alkylcoumarins. J Org Chem (2003) 0.91
Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci (2005) 0.91
Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm (Vienna) (2009) 0.90
Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep (2005) 0.90
Ginsenosides and their CNS targets. CNS Neurosci Ther (2010) 0.90
Olfactory training in patients with Parkinson's disease. PLoS One (2013) 0.89
Olfactory loss in Parkinson's disease. Parkinsons Dis (2011) 0.89
Improved odor sensitivity in attention-deficit/hyperactivity disorder. Biol Psychiatry (2008) 0.88
Iron-dependent functions of mitochondria--relation to neurodegeneration. J Neural Transm (Vienna) (2010) 0.88
Utility of measuring vitamin B12 and its active fraction, holotranscobalamin, in neurological vitamin B12 deficiency syndromes. J Neurol (2010) 0.88
Expression and localization of nuclear proteins in autosomal-dominant Emery-Dreifuss muscular dystrophy with LMNA R377H mutation. BMC Cell Biol (2004) 0.88
Sleep and non-motor symptoms in Parkinson's disease. J Neural Transm (Vienna) (2013) 0.87
Immediate effects of deep brain stimulation of the subthalamic nucleus on nonmotor symptoms in Parkinson's disease. Parkinsonism Relat Disord (2012) 0.87
Prediction of outcome in neurogenic oropharyngeal dysphagia within 72 hours of acute stroke. J Stroke Cerebrovasc Dis (2011) 0.86
Health-related quality of life in multiple system atrophy and progressive supranuclear palsy. Neurodegener Dis (2011) 0.86
Recent advances in benefits and hazards of engineered nanoparticles. Environ Toxicol Pharmacol (2012) 0.86
Dementia in idiopathic Parkinson's syndrome. J Neurol (2004) 0.85
Thymoquinone ameliorates lead-induced brain damage in Sprague Dawley rats. Exp Toxicol Pathol (2013) 0.85
Beyond tremor and rigidity: non-motor features of Parkinson's disease. J Neural Transm (Vienna) (2009) 0.85
Protective effects of resveratrol on glutamate-induced damages in murine brain cultures. J Neural Transm (Vienna) (2013) 0.84
Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures. Phytomedicine (2012) 0.84
Salivary and serum chromogranin A and α-amylase in periodontal health and disease. J Periodontol (2012) 0.84
Cardiovascular autonomic testing in extrapyramidal disorders. J Neurol Sci (2011) 0.84
Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord (2008) 0.84
Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord (2010) 0.84
Mitochondrial dysfunction in Parkinson's disease--revisited. Neurol Neurochir Pol (2007) 0.83
Interleukin-1beta-induced prostaglandin E2 production by human gingival fibroblasts is upregulated by glycine. J Periodontol (2005) 0.83
Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction. Mov Disord (2006) 0.83
Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atheroscler Suppl (2009) 0.83
Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord (2007) 0.83
A new dopaminergic nigro-olfactory projection. Acta Neuropathol (2015) 0.82
Static posturography in aging and Parkinson's disease. Front Aging Neurosci (2012) 0.82
Different diagnostic criteria for Parkinson disease: what are the pitfalls? J Neural Transm (Vienna) (2013) 0.82
The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J Neurochem (2010) 0.82
Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease. BMC Neurol (2011) 0.82
Effects of epigallocatechin gallate on rotenone-injured murine brain cultures. J Neural Transm (Vienna) (2009) 0.82
Association of sleep apnea with clinically silent microvascular brain tissue changes in acute cerebral ischemia. J Neurol (2013) 0.82
Effects of rasagiline on olfactory function in patients with Parkinson’s disease. Mov Disord (2013) 0.81
Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture. J Neurochem (2006) 0.81
Switching and combining of dopamine agonists. J Neurol (2004) 0.81
Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can J Neurol Sci (2010) 0.81
Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol In Vitro (2007) 0.81
Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report. Mov Disord (2008) 0.81
Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study. J Neurol (2009) 0.81
Whole blood genome-wide expression profiling and network analysis suggest MELAS master regulators. Neurol Res (2011) 0.80
Emergency transfer of acute stroke patients within the East Saxony telemedicine stroke network: a descriptive analysis. Int J Stroke (2013) 0.79
Mechanisms underlying and medical management of L-Dopa-associated motor complications. J Neural Transm (Vienna) (2011) 0.79
Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age. PLoS One (2010) 0.79
Early versus delayed initiation of pharmacotherapy in Parkinson's disease. Drugs (2014) 0.79
CDP-choline reduces dopaminergic cell loss induced by MPP(+) and glutamate in primary mesencephalic cell culture. Int J Neurosci (2007) 0.79
Computed tomographically-controlled injection of botulinum toxin into the longus colli muscle in severe anterocollis. Mov Disord (2004) 0.79
Nitric oxide production, systemic inflammation and lipid metabolism in periodontitis patients: possible gender aspect. J Clin Periodontol (2013) 0.79
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease. Neurology (2013) 0.78
Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study. Pain Med (2011) 0.78
Early sleep apnea screening on a stroke unit is feasible in patients with acute cerebral ischemia. J Neurol (2012) 0.78
Prefrontal cortex dysfunction and depression in atypical parkinsonian syndromes. Mov Disord (2007) 0.78
Olfactory FMRI in patients with Parkinson's disease. Front Integr Neurosci (2010) 0.78
Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. PLoS One (2011) 0.78
Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem (2013) 0.78